Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature

Chiara Pilotto*, Ismail Beshlawi, Adam Thomas, Richard G. Grundy

*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلةمراجعة النظراء

1 اقتباس (Scopus)

ملخص

Background: Bevacizumab (BVZ) is a vascular endothelial growth factor inhibitor that has been widely accepted since its introduction into the cancer pharmacopoeia. Anecdotal reports suggested improvements in vision in children with visual pathway glioma. Case presentation: We report a boy with visual pathway glioma whose vision had deteriorated significantly on vincristine and carboplatin, to the point that he was registered blind. Following bevacizumab therapy, there was a dramatic improvement in vision with reduction in tumour volume. However, following 20 doses of BVZ given over 19 months, he developed a significant cerebrovascular stenosis. Conclusion: The BVZ-induced cerebrovascular diseases in children are extremely rare but potentially serious. Importantly, stenosis has not been previously described in literature.

اللغة الأصليةEnglish
الصفحات (من إلى)781-785
عدد الصفحات5
دوريةChild's Nervous System
مستوى الصوت34
رقم الإصدار4
المعرِّفات الرقمية للأشياء
حالة النشرPublished - أبريل 1 2018
منشور خارجيًانعم

ASJC Scopus subject areas

  • ???subjectarea.asjc.2700.2735???
  • ???subjectarea.asjc.2700.2728???

بصمة

أدرس بدقة موضوعات البحث “Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا